TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of children developing early symptoms leading to diagnosis of a rare genetic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cost of surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Activities of Daily Living Function Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Points of improvement in the Single Item Dry Eye Questionnaire (SIDEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Points of improvement about the Ocular Surface Disease Index (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Points of improvement in the National Eye Institute 25-item Visual Function Questionnaire (NEI-VFQ25)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Points of improvement in the Change in Dry Eye Symptoms Questionnaire (CDES-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of improvement in corneal conjunctivalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in semi-quantitative scale (SQS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular accidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in albuminuria (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increased disease activity after colonoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Observation of 18F-DCFPyL lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of cone beam CTs (CBCTs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of splint modifications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Investigator Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycosylated hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Favorable response to FcRn inhibitors therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of LARC (IUD or progestin implant)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dysfunction index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical evolution in liver transplant patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current H. pylori infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline Adult Investigator Symptom Rating Scale (AISRS) at six months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Behavior Rating Scale of Executive Function - Adult Version (BRIEF-A) at six months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Learning and Study Strategies Inventory (LASSI) at six months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fibrosis improvement (≥ 1 stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in steatosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: prognosis of patients with osteoarticular infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state AUC of Orforglipron (Fed State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Cmax of Orforglipron (Fed State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the AST/ALT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in ECCA acne scar score from baseline at week 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of effective skin lesion clearance rate in the 20th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinically Significant Change From Baseline in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically Significant Change From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fugl-Meyer Lower Extremity (FMLE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new and/or enlarging T2 lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: major perioperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: change in hematocrit level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delirium Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: No disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Epidemiological impact of long-acting antiretrovirals
Endpoint domain: Mortality/survival
Primary endpoint: Cost-effectiveness of long-acting antiretrovirals
Endpoint domain: Resource use
Primary endpoint: Quality of life following periapical surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Radiographic healing (2D and 3D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slit Lamp Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Imaging with the NUVISION NAV Ultrasound Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serious Adverse Events (SAEs) Within 7 Days of Index Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Complete data collection rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in peak TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Olomorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from time zero to infinity (AUC0-inf) of Olomorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-34 levels in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oscillometry - Reactance (AX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-Cog11 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Annualized Spontaneous Bleeding Rate (AsBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants who develop FVIII inhibitors
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Annualised exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of high-intensity interval training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of participants with urinary calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Location of urinary calculi in the participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of analgesics consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Digital Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemodynamic phenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-tz of BI 3776528 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BI 3776528 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fundamental movement skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic single leg stance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye Hand Coordination Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of treatment change of OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of treatment change of BD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Myths Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hendrick Sexual Attitudes Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistence in treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Baseline-adjusted total eicosapentaenoic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline-adjusted L-5-methyltetrahydrofolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: monocyte chemotactic protein-1 (MCP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: oxidized low-density lipoprotein cholesterol (oxLDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Child Emotional and Behavioural Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control during fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental reported experience of anal dilatation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hand Held Dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9 peg hole test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant bone changes in width buccal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: peri-implant bone changes in width palatal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: peri-implant bone changes in height buccal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: peri-implant bone changes in height palatal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biomedical HIV prevention uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-reported momentary suicidal urges and intent
Endpoint domain: Adverse events/effects
Primary endpoint: International Cooperative Ataxia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the SCORAD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comack-Lehane Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of tricuspid regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with biopsy-proven HGAIN (AIN-2/3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vertical jumping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20m Sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immune checkpoint inhibitors (ICI)-induced colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Alcohol Use Negative Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of respiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of oxygenation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Comparison of CT and LUS findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in goblet cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of Massachusetts State Quitline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utilization of the National Cancer Institute SmokefreeTXT service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utilization of clinic or hospital-based smoking cessation services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Muscle assessment score (MAsS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splenic hilum nodal metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Use of complementary and alternative medicine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Primary patency rate of target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing Grade 3 or higher treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing Grade 3 or higher treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Symptom Resolution
Endpoint domain: Adverse events/effects
Primary endpoint: Bestest balance evaluation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TDCSs adverse effects questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Disease Activity Score 28 (DAS28(CRP))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with disease flares
Endpoint domain: Adverse events/effects
Primary endpoint: Liver Fat Percentage (on MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma mevalonate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients completing the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Mean vertigo score (MVS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in depressive symptoms (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in depressive symptoms (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in depressive symptoms (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of the organisation of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Detection of atrial fibrillation/atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Disability Index (PDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of chemotherapy-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the IBD Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Donor site morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lung atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: gastrointestinal mucositis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Muscle Spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Nervous Conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Upper Limb Pain Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Upper Limb Pain to Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease (MRD) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA Clearance Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in Fast Fourier Transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Topographic distribution of the frequency bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dominant EEG frequency localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence rate of R reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in working memory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in global cognition capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative pain 4 hours after tonsillectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised-Prenatal Coping Inventory (NuPCI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Healthfulness of participants' grocery selections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 17-Item Hamilton Depression Rating Scale Responders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful catheter insertion at first skin puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of IMT Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reactive Oxygen Species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorbed radiation dose in kidneys and selected organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 177Lu-PSMA-617
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum plasma concentration (Cmax) of 177Lu-PSMA-617
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune Related Adverse Events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of RVF virus exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Burping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the Natural Look
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight bearing lunge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily feelings of social connection
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 28-day weaning rate from invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: severity of knee osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes